Please sign in to follow a disease.
Anterogen Co., Ltd.
Clinical trials sponsored by Anterogen Co., Ltd., explained in plain language.
A South Korean biotech company developing cell and gene therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Could your own fat cells heal Crohn's fistulas? new trial tests it
Disease control OngoingThis Phase 3 trial tests whether injecting a patient's own fat-derived stem cells, along with a glue, can close fistulas caused by Crohn's disease. 46 adults with Crohn's and at least one fistula are taking part. The main goal is to see if the fistula closes completely.
Phase 3 • Sponsor: Anterogen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New knee osteoarthritis treatment shows promise in early human test
Disease control OngoingThis early-phase trial is testing a new biological treatment called ANT-301 in 6 people with severe knee osteoarthritis. The main goal is to check safety, but researchers will also measure pain and knee function. If safe, larger studies could follow to see if it truly helps.
Phase 1 • Sponsor: Anterogen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC